Skip to main content

Advertisement

SpringerLink
Log in

Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The Japan Cord Blood Bank Network (JCBBN) reports the treatment of 22 children with acute myeloid leukemia (AML) who received umbilical cord blood transplantation from unrelated donors (CBT) as their second hematopoietic stem cell transplantation (HSCT). Provided by the JCBBN, between February 1997 and September 2006, 22 patients had CBT as a second HSCT. In the initial HSCT, eight received autologous, seven received CBT, and the remaining had allogenic BMT. At the time of CBT as a second HSCT, seven were in the second complete remission (CR2), two in the third CR (CR3), the remaining were not in remission. Reduced intensity conditioning (RIC) conducted for 10 cases and myeloablative conditioning (MAC) for 12 cases. The overall survival rate was 31.3%, 5 years after CBT. Second complete remission at second transplantation was favorable prognosis (58.3 ± 18.6%, compared with 17.1 ± 10.8% for the non-CR group. Mortality after CBT as a second HSCT accounted for 15 cases, 8 from treatment-related mortality. In conclusion, CBT combined with RIC as second HSCT may be useful against a recurrence of AML in children after the initial HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang M-J, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34:721–7.

    Article  CAS  PubMed  Google Scholar 

  2. Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2003;9:706–13.

    Article  PubMed  Google Scholar 

  3. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304–13.

    Article  CAS  PubMed  Google Scholar 

  4. Isoyama K, Ohnuma K, Ikuta K, Toyoda Y, Nakajima F, Yamada K, et al. Unrelated cord blood transplantation for second hemopoietic stem cell transplantation. Pediatr Int. 2003;45:268–74.

    Article  PubMed  Google Scholar 

  5. Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant. 2008;41:173–82.

    Article  CAS  PubMed  Google Scholar 

  6. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.

    Article  CAS  PubMed  Google Scholar 

  7. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461–6.

    Article  CAS  PubMed  Google Scholar 

  8. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant. 1997;19:709–19.

    Article  CAS  PubMed  Google Scholar 

  9. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, et al. Hernessing graft-versus-malignancy; non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000;111:18–29.

    Article  CAS  PubMed  Google Scholar 

  10. Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga Ldel C, Gonzalez-Llano O, Jaime-Perez JC, Lopez-Martinez B, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant. 2003;9:157–61.

    Article  PubMed  Google Scholar 

  11. Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33 + acute myeloid leukemia. Clin Cancer Res. 2005;11(19 Part 2):7164s–70s.

    Article  CAS  PubMed  Google Scholar 

  12. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol. 2000;28:1096–104.

    Article  CAS  PubMed  Google Scholar 

  13. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105:879–85.

    Article  CAS  PubMed  Google Scholar 

  14. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, et al. for the Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for blood and marrow transplantation. J Clin Oncol. 2001;19:3675–84.

    Article  Google Scholar 

  15. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant. 2007;13:116–23.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported (in part) by a Research Grant for Tissue Engineering (H17-014), and a Research Grant for Allergic Disease and Immunology (H20-015) from the Japanese Ministry of Health, Labor, and Welfare.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

    M. Oda

  2. Department of Pediatrics, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, 227-8501, Japan

    K. Isoyama

  3. Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan

    E. Ito

  4. Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan

    M. Inoue

  5. Department of Pediatrics, Ibaraki Children’s Hospital, Ibaraki, Japan

    M. Tsuchida

  6. Division of Hemato-oncology/Regulation Medicine, Kanagawa Children’s Medical Center, Kanagawa, Japan

    H. Kigasawa

  7. Division of Hematology/Oncology, Children’s Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

    K. Kato

  8. Department of Cell Transplantation, Tokai University School of Medicine, Isehara, Japan

    S. Kato

Authors
  1. M. Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Isoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Tsuchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Kigasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Isoyama.

Appendix

Appendix

1.1 Transplant centers

Transplant centers that performed CBT by the JCBBN coordination and produced follow-up reports are: Division of Pediatric Oncology, National Cancer Center Hospital, Tokyo; Division of Hematology/Oncology, Kanagawa Children’s Medical Center, Yokohama; Department of Pediatrics, Ibaraki Children’s Hospital, Mito; Division of pediatrics, Osaka City General Hospital, Osaka; Department of Pediatrics, Saitama Medical university, Iruma; Division of Hematology/Oncology, Saitama Children’s Medical Center, Iwatsuki; Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka; Department of Pediatrics, Hamanomachi Hospital, Fukuoka; Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki; Division of Pediatric Hematology/Oncology, Nagoya Red Cross First Hospital, Nagoya; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo; Department of Pediatrics, Tottori University Faculty of Medicine, Yonago; Department of Pediatrics, Faculty of Medicine, University of the Ryukyus, Nishihara; Department of Pediatric Hematology and Oncology, Tohoku University School of Medicine, Sendai; Hamamatsu University School of Medicine, Hamamatsu; Department of Pediatrics, University of Occupational and Environmental Health, Kitakyushu; Department of Hematology-Oncology, Tokyo Metropolitan Kiyose Children’s Hospital, Kiyose; Department of Pediatrics, University of Tokyo, Tokyo; Department of Pediatrics, Osaka City University Graduate school of Medicine.

About this article

Cite this article

Oda, M., Isoyama, K., Ito, E. et al. Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Int J Hematol 89, 374–382 (2009). https://doi.org/10.1007/s12185-009-0266-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0266-9

Keywords

Search

Navigation